{
    "info": {
        "nct_id": "NCT06708455",
        "official_title": "Phase 2 Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Malignant Melanoma",
        "inclusion_criteria": "1. Male or female patients ≥ 18 years of age.\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and an estimated life expectancy of ≥ 3 months.\n3. Patients with unresectable or metastatic melanoma (Stage IIIc or Stage IV).\n4. Prior to enrollment, documented refractory status to the most recent regimen, which must include an anti-PD-(L)1 monoclonal antibody, as defined by lack of response after at least two cycles of therapy or relapse within 12-months of initiation of the anti-PD- (L)1-containing therapy.\n5. For patients with BRAF V600 mutation-positive tumors, prior therapy with a BRAF inhibitor alone or in combination with a MEK inhibitor.\n6. Presence of measurable disease to permit monitoring by iRECISTv1.1 Criteria.\n7. Must have a potential source of autologous T cells potentially sufficient to manufacture RAPA-201 cells, as defined by a circulating absolute lymphocyte count (ALC) of ≥ 500 cells/μL.\n8. Patients must be ≥ two weeks from last solid tumor cancer chemotherapy, major surgery, radiation therapy and/or participation in investigational trials.\n9. Patients must have recovered from clinical immunotherapy-related toxicities [resolution of CTCAE (v5) toxicity to a value of ≤ 1; with the exception of alopecia, vitiligo, and endocrinopathy stable on hormone replacement].\n10. Hematologic parameters of: Absolute neutrophil count (ANC) of ≥ 1500 cells/μL, Platelet count ≥ 100,000 cells/μL, and Hemoglobin of ≥ 9 grams/μL.\n11. Calculated creatinine clearance of ≥ 40 mL/min.\n12. Ejection fraction (EF) by MUGA or 2-D echocardiogram within institution normal limits, with an EF level of ≥ 45%.\n13. Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 3 x upper limit of normal (ULN) (or ≤ ULN if patient has liver metastasis).\n14. Bilirubin ≤ 2.0 mg/dL (if Gilbert&#39;s disease, ≤ 3.0 mg/dL).\n15. No history of abnormal bleeding tendency (as defined by any inherited coagulation defect or history of internal bleeding).\n16. Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.\n\nExclusion Criteria\n\n1. Other active malignancy (except non-melanoma skin cancer).\n2. Life expectancy &lt; 3 months.\n3. Seropositivity for HIV, hepatitis B, or hepatitis C, unless such conditions are in stable condition using adequate treatment.\n4. Uncontrolled hypertension.\n5. Cerebrovascular accident within 6 months of enrollment.\n6. Myocardial infarction within 6 months of enrollment.\n7. NYHA class III/IV congestive heart failure.\n8. Uncontrolled angina/ischemic heart disease.\n9. Cancer metastasis to the central nervous system, unless such metastasis has been adequately treated.\n10. Pregnant or breastfeeding patients.\n11. Women of childbearing potential, or males who have a partner of childbearing potential, who are unwilling to practice contraception.\n12. Patients may be excluded at the discretion of the PI or if it is deemed that allowing participation would represent an unacceptable medical or psychiatric risk.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and an estimated life expectancy of ≥ 3 months.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "estimated life expectancy of ≥ 3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "minimum duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Patients with unresectable or metastatic melanoma (Stage IIIc or Stage IV).",
            "criterions": [
                {
                    "exact_snippets": "unresectable or metastatic melanoma (Stage IIIc or Stage IV)",
                    "criterion": "melanoma",
                    "requirements": [
                        {
                            "requirement_type": "disease_status",
                            "expected_value": [
                                "unresectable",
                                "metastatic"
                            ]
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "IIIc",
                                "IV"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Prior to enrollment, documented refractory status to the most recent regimen, which must include an anti-PD-(L)1 monoclonal antibody, as defined by lack of response after at least two cycles of therapy or relapse within 12-months of initiation of the anti-PD- (L)1-containing therapy.",
            "criterions": [
                {
                    "exact_snippets": "documented refractory status to the most recent regimen",
                    "criterion": "refractory status to the most recent regimen",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "refractory"
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "the most recent regimen, which must include an anti-PD-(L)1 monoclonal antibody",
                    "criterion": "most recent regimen contents",
                    "requirements": [
                        {
                            "requirement_type": "inclusion",
                            "expected_value": "anti-PD-(L)1 monoclonal antibody"
                        }
                    ]
                },
                {
                    "exact_snippets": "lack of response after at least two cycles of therapy",
                    "criterion": "response to anti-PD-(L)1-containing therapy",
                    "requirements": [
                        {
                            "requirement_type": "response",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "number of cycles",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "cycles"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "relapse within 12-months of initiation of the anti-PD- (L)1-containing therapy",
                    "criterion": "relapse after initiation of anti-PD-(L)1-containing therapy",
                    "requirements": [
                        {
                            "requirement_type": "relapse",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time from initiation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. For patients with BRAF V600 mutation-positive tumors, prior therapy with a BRAF inhibitor alone or in combination with a MEK inhibitor.",
            "criterions": [
                {
                    "exact_snippets": "patients with BRAF V600 mutation-positive tumors",
                    "criterion": "BRAF V600 mutation status",
                    "requirements": [
                        {
                            "requirement_type": "mutation",
                            "expected_value": "V600"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior therapy with a BRAF inhibitor alone or in combination with a MEK inhibitor",
                    "criterion": "prior therapy with BRAF and/or MEK inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "prior therapy",
                            "expected_value": [
                                "BRAF inhibitor",
                                "BRAF inhibitor in combination with MEK inhibitor"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Presence of measurable disease to permit monitoring by iRECISTv1.1 Criteria.",
            "criterions": [
                {
                    "exact_snippets": "Presence of measurable disease to permit monitoring by iRECISTv1.1 Criteria.",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "measurability_by",
                            "expected_value": "iRECISTv1.1 Criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Must have a potential source of autologous T cells potentially sufficient to manufacture RAPA-201 cells, as defined by a circulating absolute lymphocyte count (ALC) of ≥ 500 cells/μL.",
            "criterions": [
                {
                    "exact_snippets": "potential source of autologous T cells potentially sufficient to manufacture RAPA-201 cells",
                    "criterion": "source of autologous T cells",
                    "requirements": [
                        {
                            "requirement_type": "potential sufficiency for RAPA-201 manufacture",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "circulating absolute lymphocyte count (ALC) of ≥ 500 cells/μL",
                    "criterion": "circulating absolute lymphocyte count (ALC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 500,
                                "unit": "cells/μL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Patients must have recovered from clinical immunotherapy-related toxicities [resolution of CTCAE (v5) toxicity to a value of ≤ 1; with the exception of alopecia, vitiligo, and endocrinopathy stable on hormone replacement].",
            "criterions": [
                {
                    "exact_snippets": "Patients must have recovered from clinical immunotherapy-related toxicities [resolution of CTCAE (v5) toxicity to a value of ≤ 1",
                    "criterion": "clinical immunotherapy-related toxicities",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "CTCAE v5 grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of alopecia, vitiligo, and endocrinopathy stable on hormone replacement",
                    "criterion": "endocrinopathy",
                    "requirements": [
                        {
                            "requirement_type": "stability on hormone replacement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Hematologic parameters of: Absolute neutrophil count (ANC) of ≥ 1500 cells/μL, Platelet count ≥ 100,000 cells/μL, and Hemoglobin of ≥ 9 grams/μL.",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) of ≥ 1500 cells/μL",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "cells/μL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Platelet count ≥ 100,000 cells/μL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "cells/μL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Hemoglobin of ≥ 9 grams/μL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "grams/μL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Calculated creatinine clearance of ≥ 40 mL/min.",
            "criterions": [
                {
                    "exact_snippets": "Calculated creatinine clearance of ≥ 40 mL/min.",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Ejection fraction (EF) by MUGA or 2-D echocardiogram within institution normal limits, with an EF level of ≥ 45%.",
            "criterions": [
                {
                    "exact_snippets": "Ejection fraction (EF) by MUGA or 2-D echocardiogram within institution normal limits",
                    "criterion": "ejection fraction (EF)",
                    "requirements": [
                        {
                            "requirement_type": "measurement_method",
                            "expected_value": [
                                "MUGA",
                                "2-D echocardiogram"
                            ]
                        },
                        {
                            "requirement_type": "reference_range",
                            "expected_value": "within institution normal limits"
                        }
                    ]
                },
                {
                    "exact_snippets": "EF level of ≥ 45%",
                    "criterion": "ejection fraction (EF)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 3 x upper limit of normal (ULN) (or ≤ ULN if patient has liver metastasis).",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) ... ≤ 3 x upper limit of normal (ULN) (or ≤ ULN if patient has liver metastasis)",
                    "criterion": "Aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (if patient has liver metastasis)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) ... ≤ 3 x upper limit of normal (ULN) (or ≤ ULN if patient has liver metastasis)",
                    "criterion": "Alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (if patient has liver metastasis)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Patients must be ≥ two weeks from last solid tumor cancer chemotherapy, major surgery, radiation therapy and/or participation in investigational trials.",
            "criterions": [
                {
                    "exact_snippets": "Patients must be ≥ two weeks from last solid tumor cancer chemotherapy",
                    "criterion": "time since last solid tumor cancer chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients must be ≥ two weeks from last ... major surgery",
                    "criterion": "time since last major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients must be ≥ two weeks from last ... radiation therapy",
                    "criterion": "time since last radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients must be ≥ two weeks from last ... participation in investigational trials",
                    "criterion": "time since last participation in investigational trials",
                    "requirements": [
                        {
                            "requirement_type": "time since last participation",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Male or female patients ≥ 18 years of age.",
            "criterions": [
                {
                    "exact_snippets": "Male or female patients",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "≥ 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. No history of abnormal bleeding tendency (as defined by any inherited coagulation defect or history of internal bleeding).",
            "criterions": [
                {
                    "exact_snippets": "No history of abnormal bleeding tendency",
                    "criterion": "abnormal bleeding tendency",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "any inherited coagulation defect",
                    "criterion": "inherited coagulation defect",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "history of internal bleeding",
                    "criterion": "internal bleeding",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.",
            "criterions": [
                {
                    "exact_snippets": "Voluntary written consent must be given before performance of any study related procedure not part of standard medical care",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "voluntary",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "written",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "given before performance of any study related procedure not part of standard medical care",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "consent may be withdrawn by the patient at any time without prejudice to future medical care",
                    "criterion": "right to withdraw consent",
                    "requirements": [
                        {
                            "requirement_type": "withdrawal allowed at any time",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "no prejudice to future medical care",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Other active malignancy (except non-melanoma skin cancer).",
            "criterions": [
                {
                    "exact_snippets": "Other active malignancy (except non-melanoma skin cancer)",
                    "criterion": "other active malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "non-melanoma skin cancer"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Cerebrovascular accident within 6 months of enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Cerebrovascular accident within 6 months of enrollment.",
                    "criterion": "cerebrovascular accident",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Uncontrolled hypertension.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled hypertension",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Myocardial infarction within 6 months of enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Myocardial infarction within 6 months of enrollment",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Seropositivity for HIV, hepatitis B, or hepatitis C, unless such conditions are in stable condition using adequate treatment.",
            "criterions": [
                {
                    "exact_snippets": "Seropositivity for HIV",
                    "criterion": "HIV seropositivity",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "disease stability",
                            "expected_value": "stable condition using adequate treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Seropositivity for ... hepatitis B",
                    "criterion": "hepatitis B seropositivity",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "disease stability",
                            "expected_value": "stable condition using adequate treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Seropositivity for ... hepatitis C",
                    "criterion": "hepatitis C seropositivity",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "disease stability",
                            "expected_value": "stable condition using adequate treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Pregnant or breastfeeding patients.",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Uncontrolled angina/ischemic heart disease.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled angina",
                    "criterion": "angina",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Uncontrolled ... ischemic heart disease",
                    "criterion": "ischemic heart disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Cancer metastasis to the central nervous system, unless such metastasis has been adequately treated.",
            "criterions": [
                {
                    "exact_snippets": "Cancer metastasis to the central nervous system",
                    "criterion": "cancer metastasis to the central nervous system",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "unless such metastasis has been adequately treated",
                    "criterion": "cancer metastasis to the central nervous system",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Women of childbearing potential, or males who have a partner of childbearing potential, who are unwilling to practice contraception.",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential ... unwilling to practice contraception",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "willingness to practice contraception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "males who have a partner of childbearing potential ... unwilling to practice contraception",
                    "criterion": "contraception use (male partner)",
                    "requirements": [
                        {
                            "requirement_type": "willingness to practice contraception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. NYHA class III/IV congestive heart failure.",
            "criterions": [
                {
                    "exact_snippets": "NYHA class III/IV congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Patients may be excluded at the discretion of the PI or if it is deemed that allowing participation would represent an unacceptable medical or psychiatric risk.",
            "criterions": [
                {
                    "exact_snippets": "excluded at the discretion of the PI",
                    "criterion": "PI discretion",
                    "requirements": [
                        {
                            "requirement_type": "exclusion at PI discretion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unacceptable medical or psychiatric risk",
                    "criterion": "medical or psychiatric risk",
                    "requirements": [
                        {
                            "requirement_type": "risk level",
                            "expected_value": "unacceptable"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "14. Bilirubin ≤ 2.0 mg/dL (if Gilbert&#39;s disease, ≤ 3.0 mg/dL).",
            "criterions": [
                {
                    "exact_snippets": "Bilirubin ≤ 2.0 mg/dL (if Gilbert's disease, ≤ 3.0 mg/dL)",
                    "criterion": "bilirubin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.0,
                                        "unit": "mg/dL"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (if Gilbert's disease)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3.0,
                                        "unit": "mg/dL"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Exclusion Criteria",
            "criterions": []
        },
        {
            "line": "2. Life expectancy &lt; 3 months.",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy < 3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}